阿米卡星肾毒性。发病率、临床病程及危险因素。一项在教学医院开展的前瞻性研究。 - Suppr

Amikacin nephrotoxicity. Incidence, clinical course and risk factors. A prospective study in a teaching hospital.

Gamba G, Arizpe D, Ferral H, Contreras A M, Cortés J, Mendoza A, Malé R, Viniegra L, Peña J C

Rev Invest Clin. 1988 Apr-Jun;40(2):135-40.

Abstract

摘要

Rev Invest Clin. 1988 Apr-Jun;40(2):135-40.

Rev Invest Clin. 1994 Jan-Feb;46(1):37-43.

Johns Hopkins Med J. 1978 Mar;142(3):85-90.

Am J Ther. 2008 Mar-Apr;15(2):131-6. doi: 10.1097/MJT.0b013e31815adfde.

Rev Invest Clin. 1990 Jul-Sep;42(3):204-9.

Rev Invest Clin. 1990 Apr-Jun;42(2):93-8.

Fundam Clin Pharmacol. 2009 Aug;23(4):515-20. doi: 10.1111/j.1472-8206.2009.00702.x.

Acta Pol Pharm. 2005 Nov-Dec;62(6):491-5.

Acta Pol Pharm. 2005 Nov-Dec;62(6):485-90.

Dev Pharmacol Ther. 1982;5(1-2):33-46.

Antimicrob Agents Chemother. 1989 Jun;33(6):973-6. doi: 10.1128/AAC.33.6.973.

20分钟写一篇综述，助力文献阅读效率提升50倍。

大模型驱动的PubMed中文搜索引擎

学术文献翻译模型，支持多种主流文档格式。